MedTrace Logo

Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

NCT01422772 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-10-03

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety of VM202 (Engensis) direct injection into the cardiac muscles of the coronary artery territory where complete revascularization could not be done even through Coronary Artery Bypass Graft (CABG).

Conditions

  • Ischemic Heart Disease

Interventions

BIOLOGICAL

VM202-0.5 mg

0.5 mg intramyocardial injection

BIOLOGICAL

VM202-1.0 mg

1 mg intramyocardial injection

BIOLOGICAL

VM202-2.0 mg

2 mg intramyocardial injection

Sponsors & Collaborators

  • Helixmith Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Gibong Kim, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-02-28
Completion
2014-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01422772 on ClinicalTrials.gov